08:37 AM EDT, 03/12/2025 (MT Newswires) -- Emergent BioSolutions ( EBS ) said Wednesday that it has agreed to make a strategic investment in Rocketvax's parent company, Swiss Rockets.

Financial details of the investment were not disclosed.

Emergent said it will fund research, infrastructure development, and the expansion of Swiss Rockets' biotech portfolio.

Emergent also said it will handle US production and sales of four Rocketvax drug candidates for infectious diseases, cancer, and autoimmune disorders.